Advances of mammalian mechanistic target of rapamycin inhibitors in reducing human cytomegalovirus infection in renal transplantation recipients

Abstract:

Human cytomegalovirus(HCMV) is one of the eight herpes viruses that can infect human, it often infects people with low immunity, especially in patients after renal transplantation, patients with advanced acquired immunodefiency syndrome, and newborns. Mammalian mechanistic target of rapamycin (mTOR) is a serine/threonine protein kinase(AKT) of the downstream of acid-inositol-3-kinase (PI3K) family, which can affect all stages of HCMV infection. mTOR inhibitor(mTORi)can be used as immunosuppressant in patients after renal transplantation, it can reduce incidence of HCMV infection. This paper reviews the advance of mTORi in reducing HCMV infection in renal transplantation recipients.